HomeCompareARPO vs PM

ARPO vs PM: Dividend Comparison 2026

ARPO yields 90.91% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARPO wins by $2.62M in total portfolio value
10 years
ARPO
ARPO
● Live price
90.91%
Share price
$2.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.67M
Annual income
$842,999.04
Full ARPO calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — ARPO vs PM

📍 ARPO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARPOPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARPO + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARPO pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARPO
Annual income on $10K today (after 15% tax)
$7,727.27/yr
After 10yr DRIP, annual income (after tax)
$716,549.18/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, ARPO beats the other by $714,430.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARPO + PM for your $10,000?

ARPO: 50%PM: 50%
100% PM50/50100% ARPO
Portfolio after 10yr
$1.36M
Annual income
$422,745.53/yr
Blended yield
31.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ARPO
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-2.4
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARPO buys
0
PM buys
0
No recent congressional trades found for ARPO or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARPOPM
Forward yield90.91%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$2.67M$49.6K
Annual income after 10y$842,999.04$2,492.02
Total dividends collected$2.36M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ARPO vs PM ($10,000, DRIP)

YearARPO PortfolioARPO Income/yrPM PortfolioPM Income/yrGap
1← crossover$19,791$9,090.91$11,648$408.29+$8.1KARPO
2$37,991$16,814.71$13,589$495.90+$24.4KARPO
3$70,817$30,166.17$15,877$603.21+$54.9KARPO
4$128,326$52,552.16$18,580$734.88+$109.7KARPO
5$226,308$88,999.24$21,781$896.75+$204.5KARPO
6$388,835$146,685.82$25,578$1,096.12+$363.3KARPO
7$651,597$235,543.05$30,092$1,342.17+$621.5KARPO
8$1,066,101$368,892.48$35,470$1,646.46+$1.03MARPO
9$1,704,801$564,073.19$41,892$2,023.58+$1.66MARPO
10$2,667,136$842,999.04$49,578$2,492.02+$2.62MARPO

ARPO vs PM: Complete Analysis 2026

ARPOStock

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Full ARPO Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ARPO vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARPO vs SCHDARPO vs JEPIARPO vs OARPO vs KOARPO vs MAINARPO vs MOARPO vs BTIARPO vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.